Literature DB >> 3216028

Flunarizine-induced parkinsonism in the elderly.

F Benvenuti1, A Baroni, S Bandinelli, L Ferrucci, R Corradetti, T Pantaleo.   

Abstract

Twenty-seven patients (19 women and 8 men, ages 63 to 88 years; mean, 74 years) displayed mild to moderate parkinsonism and altered ballistic motor performances during long-term flunarizine treatment. One month after, flunarizine withdrawal, 20 patients showed clear-cut improvements in both clinical features and ballistic motor performances; a complete recovery within 6 months was observed in all these patients but one, who still showed very mild slowness of movement. On the other hand, seven patients showed little clinical improvement and still maintained markedly altered ballistic motor performances 1 month after drug withdrawal. At the 2-month follow-up assessments, either they did not improve further or they deteriorated; they were successfully treated with L-dopa and, despite the ameliorations, after 12 to 24 months they still have definite parkinsonian syndrome. The authors conclude that (1) flunarizine, even at the recommended dose (10 mg daily), can induce reversible parkinsonism, at least in subjects older than 60; (2) the persistence of a marked symptomatology 2 months after flunarizine withdrawal should lead to starting treatment with antiparkinsonism drugs; (3) the study of ballistic movements is proposed as a useful tool for objective quantification and early detection of bradykinesia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3216028     DOI: 10.1002/j.1552-4604.1988.tb03183.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

1.  A postmarketing study of flunarizine in migraine and vertigo.

Authors:  G H de Bock; J Eelhart; H W van Marwijk; T P Tromp; M P Springer
Journal:  Pharm World Sci       Date:  1997-12

2.  Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study.

Authors:  Hsiu-Li Lin; Hsiu-Chen Lin; Yuan-Fu Tseng; Shih-Chang Chen; Chien-Yeh Hsu
Journal:  Eur J Clin Pharmacol       Date:  2016-12-16       Impact factor: 2.953

3.  Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography.

Authors:  Hae-Won Shin; Jae Seung Kim; Minyoung Oh; Sooyeoun You; Young Jin Kim; Juyeon Kim; Mi-Jung Kim; Sun Ju Chung
Journal:  Neurol Sci       Date:  2014-09-18       Impact factor: 3.307

Review 4.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

5.  Nimodipine in migraine: clinical efficacy and endocrinological effects.

Authors:  R Formisano; P Falaschi; R Cerbo; A Proietti; T Catarci; R D'Urso; C Roberti; V Aloise; F Chiarotti; A Agnoli
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 6.  Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

7.  Flunarizine Induced Parkinsonism in Migraine Group: A Nationwide Population-Based Study.

Authors:  Wei Lin; Cheng-Li Lin; Chung Y Hsu; Cheng-Yu Wei
Journal:  Front Pharmacol       Date:  2019-12-19       Impact factor: 5.810

Review 8.  Current Insights into Treating Vertigo in Older Adults.

Authors:  Augusto Pietro Casani; Mauro Gufoni; Silvia Capobianco
Journal:  Drugs Aging       Date:  2021-06-23       Impact factor: 3.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.